Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.
about
Novel interactions between the HTLV antisense proteins HBZ and APH-2 and the NFAR protein family: Implications for the HTLV lifecyclesPhase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1-Associated Adult T-cell Leukemia/lymphoma.YM155 Down-Regulates Survivin and Induces P53 Up-Regulated Modulator of Apoptosis (PUMA)-Dependent in Oral Squamous Cell Carcinoma Cells.Bortezomib-based chemotherapy regimens can improve response in newly diagnosed multiple myeloma patients with bcl-2 and survivin overexpression.MicroRNA regulation and therapeutic targeting of survivin in cancer.Influence of survivin-targeted therapy on chemosensitivity in the treatment of acute myeloid leukemia.Targeting Survivin Enhances Chemosensitivity in Retinoblastoma Cells and Orthotopic Tumors.AML sensitivity to YM155 is modulated through AKT and Mcl-1.YM155, a survivin suppressant, triggers PARP-dependent cell death (parthanatos) and inhibits esophageal squamous-cell carcinoma xenografts in miceA combination of YM-155, a small molecule survivin inhibitor, and IL-2 potently suppresses renal cell carcinoma in murine model.The survivin suppressant YM155 reverses doxorubicin resistance in osteosarcoma.Sepantronium is a DNA damaging agent that synergizes with PLK1 inhibitor volasertib.YM155, a small molecule inhibitor of survivin expression, sensitizes cancer cells to hypericin-mediated photodynamic therapy.Anti-leukemic effects of the V-ATPase inhibitor Archazolid A.Striving to cure adult T-cell leukaemia/lymphoma: a role for allogeneic stem cell transplant?Targeting the proliferative and chemoresistant compartment in chronic lymphocytic leukemia by inhibiting survivin protein.
P2860
Q28397941-B7F3E8E0-8C67-4D7C-8F13-67185C513D0EQ33434322-77D52497-E7BE-4777-97CF-F3721FE08038Q33626354-C2C0BC83-47B4-47BF-AF26-01715DB78C84Q34029221-83BAFE2A-F078-4D66-9118-29624A23A619Q34991312-F93B29CB-4B75-4A00-BBBB-488669079783Q35914683-E8B2FFCB-DDE3-4C56-9858-3B30E221C665Q35981061-F677B9EE-971D-4B0E-83A7-681550298841Q35983805-D167C56A-4D8A-4164-B74C-1F3DC2A150C6Q36210899-16F21E10-2467-4339-8C81-6ABE02FDF525Q36356265-383FEAAE-87B3-4FAF-A704-EF932781D301Q36411703-E3A9D8D5-7876-4A2D-AC2C-DF0CBEB9E00EQ38366458-FF36DCEB-5310-41F5-A0AD-FC16685DFDDFQ38767465-5B308426-9A18-4257-AE4A-2A0EB8570119Q38825585-126E216F-770D-48CE-A202-1588CEA50DDCQ38952071-2F9AFCC8-97B8-429E-BF0E-0C72DDDF0175Q51749083-C330BA70-A85F-4400-9237-D09F34A4BCC9
P2860
Markedly additive antitumor activity with the combination of a selective survivin suppressant YM155 and alemtuzumab in adult T-cell leukemia.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
2013年论文
@zh
2013年论文
@zh-cn
name
Markedly additive antitumor ac ...... umab in adult T-cell leukemia.
@ast
Markedly additive antitumor ac ...... umab in adult T-cell leukemia.
@en
type
label
Markedly additive antitumor ac ...... umab in adult T-cell leukemia.
@ast
Markedly additive antitumor ac ...... umab in adult T-cell leukemia.
@en
prefLabel
Markedly additive antitumor ac ...... umab in adult T-cell leukemia.
@ast
Markedly additive antitumor ac ...... umab in adult T-cell leukemia.
@en
P2093
P2860
P1433
P1476
Markedly additive antitumor ac ...... umab in adult T-cell leukemia.
@en
P2093
Anne Keating
Cynthia A Pise-Masison
Joanna H Shih
John C Morris
John E Janik
Kevin C Conlon
Thomas A Waldmann
P2860
P304
P356
10.1182/BLOOD-2012-05-427773
P407
P577
2013-01-15T00:00:00Z